Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.

ABSTRACT:

Objectives

To describe the clinical characteristics and predictors of major outcomes in patients treated with tocilizumab (TCZ) for severe COVID-19 pneumonia.

Patients and methods

Case series of all sequential patients with severe COVID-19 pneumonia treated with TCZ at an Academic Spanish hospital (March 12 - May 2, 2020). Clinical outcomes: death, length of hospital stay. An early clinical response to TCZ (48-72 h after the administration) was assessed by variations in respiratory function markers, Brescia COVID Respiratory Severity Scale (BCRSS), inflammatory parameters, and patients' and physicians' opinion. Associations were tested by multiple logistic regression.

Results

From a cohort of 236 patients, 77 patients treated with TCZ were included (median age 62 year

SUBMITTER: Moreno-Perez O 

PROVIDER: S-EPMC7365106 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature